279 related articles for article (PubMed ID: 28202570)
1. AAV-mediated delivery of optogenetic constructs to the macaque brain triggers humoral immune responses.
Mendoza SD; El-Shamayleh Y; Horwitz GD
J Neurophysiol; 2017 May; 117(5):2004-2013. PubMed ID: 28202570
[TBL] [Abstract][Full Text] [Related]
2. Antibody neutralization poses a barrier to intravitreal adeno-associated viral vector gene delivery to non-human primates.
Kotterman MA; Yin L; Strazzeri JM; Flannery JG; Merigan WH; Schaffer DV
Gene Ther; 2015 Feb; 22(2):116-26. PubMed ID: 25503696
[TBL] [Abstract][Full Text] [Related]
3. Intramuscular administration of AAV overcomes pre-existing neutralizing antibodies in rhesus macaques.
Greig JA; Calcedo R; Grant RL; Peng H; Medina-Jaszek CA; Ahonkhai O; Qin Q; Roy S; Tretiakova AP; Wilson JM
Vaccine; 2016 Dec; 34(50):6323-6329. PubMed ID: 27817961
[TBL] [Abstract][Full Text] [Related]
4. Mapping an Adeno-associated Virus 9-Specific Neutralizing Epitope To Develop Next-Generation Gene Delivery Vectors.
Giles AR; Govindasamy L; Somanathan S; Wilson JM
J Virol; 2018 Oct; 92(20):. PubMed ID: 30089698
[TBL] [Abstract][Full Text] [Related]
5. Intraocular route of AAV2 vector administration defines humoral immune response and therapeutic potential.
Li Q; Miller R; Han PY; Pang J; Dinculescu A; Chiodo V; Hauswirth WW
Mol Vis; 2008 Sep; 14():1760-9. PubMed ID: 18836574
[TBL] [Abstract][Full Text] [Related]
6. Pre-existing antibodies to candidate gene therapy vectors (adeno-associated vector serotypes) in domestic cats.
Li P; Boenzli E; Hofmann-Lehmann R; Helfer-Hungerbuehler AK
PLoS One; 2019; 14(3):e0212811. PubMed ID: 30897117
[TBL] [Abstract][Full Text] [Related]
7. Neutralizing antibodies against AAV serotypes 1, 2, 6, and 9 in sera of commonly used animal models.
Rapti K; Louis-Jeune V; Kohlbrenner E; Ishikawa K; Ladage D; Zolotukhin S; Hajjar RJ; Weber T
Mol Ther; 2012 Jan; 20(1):73-83. PubMed ID: 21915102
[TBL] [Abstract][Full Text] [Related]
8. Transient immunosuppression allows transgene expression following readministration of adeno-associated viral vectors.
Manning WC; Zhou S; Bland MP; Escobedo JA; Dwarki V
Hum Gene Ther; 1998 Mar; 9(4):477-85. PubMed ID: 9525309
[TBL] [Abstract][Full Text] [Related]
9. Successful Repeated Hepatic Gene Delivery in Mice and Non-human Primates Achieved by Sequential Administration of AAV5
Majowicz A; Salas D; Zabaleta N; Rodríguez-Garcia E; González-Aseguinolaza G; Petry H; Ferreira V
Mol Ther; 2017 Aug; 25(8):1831-1842. PubMed ID: 28596114
[TBL] [Abstract][Full Text] [Related]
10. Long-term expression and repeated administration of AAV type 1, 2 and 5 vectors in skeletal muscle of immunocompetent adult mice.
Rivière C; Danos O; Douar AM
Gene Ther; 2006 Sep; 13(17):1300-8. PubMed ID: 16688207
[TBL] [Abstract][Full Text] [Related]
11. Successful attenuation of humoral immunity to viral capsid and transgenic protein following AAV-mediated gene transfer with a non-depleting CD4 antibody and cyclosporine.
McIntosh JH; Cochrane M; Cobbold S; Waldmann H; Nathwani SA; Davidoff AM; Nathwani AC
Gene Ther; 2012 Jan; 19(1):78-85. PubMed ID: 21716299
[TBL] [Abstract][Full Text] [Related]
12. Prevalence and long-term monitoring of humoral immunity against adeno-associated virus in Duchenne Muscular Dystrophy patients.
Leborgne C; Latournerie V; Boutin S; Desgue D; Quéré A; Pignot E; Collaud F; Charles S; Simon Sola M; Masat E; Jouen F; Boyer O; Masurier C; Mingozzi F; Veron P
Cell Immunol; 2019 Aug; 342():103780. PubMed ID: 29571923
[TBL] [Abstract][Full Text] [Related]
13. Muscle-Directed Delivery of an AAV1 Vector Leads to Capsid-Specific T Cell Exhaustion in Nonhuman Primates and Humans.
Gernoux G; Gruntman AM; Blackwood M; Zieger M; Flotte TR; Mueller C
Mol Ther; 2020 Mar; 28(3):747-757. PubMed ID: 31982038
[TBL] [Abstract][Full Text] [Related]
14. Gene Delivery of Activated Factor VII Using Alternative Adeno-Associated Virus Serotype Improves Hemostasis in Hemophiliac Mice with FVIII Inhibitors and Adeno-Associated Virus Neutralizing Antibodies.
Sun J; Hua B; Chen X; Samulski RJ; Li C
Hum Gene Ther; 2017 Aug; 28(8):654-666. PubMed ID: 28478688
[TBL] [Abstract][Full Text] [Related]
15. Bat adeno-associated viruses as gene therapy vectors with the potential to evade human neutralizing antibodies.
Li Y; Li J; Liu Y; Shi Z; Liu H; Wei Y; Yang L
Gene Ther; 2019 Jun; 26(6):264-276. PubMed ID: 31110296
[TBL] [Abstract][Full Text] [Related]
16. Humoral immunity to adeno-associated virus type 2 vectors following administration to murine and nonhuman primate muscle.
Chirmule N; Xiao W; Truneh A; Schnell MA; Hughes JV; Zoltick P; Wilson JM
J Virol; 2000 Mar; 74(5):2420-5. PubMed ID: 10666273
[TBL] [Abstract][Full Text] [Related]
17. Overcoming preexisting humoral immunity to AAV using capsid decoys.
Mingozzi F; Anguela XM; Pavani G; Chen Y; Davidson RJ; Hui DJ; Yazicioglu M; Elkouby L; Hinderer CJ; Faella A; Howard C; Tai A; Podsakoff GM; Zhou S; Basner-Tschakarjan E; Wright JF; High KA
Sci Transl Med; 2013 Jul; 5(194):194ra92. PubMed ID: 23863832
[TBL] [Abstract][Full Text] [Related]
18. AAV Vector Immunogenicity in Humans: A Long Journey to Successful Gene Transfer.
Verdera HC; Kuranda K; Mingozzi F
Mol Ther; 2020 Mar; 28(3):723-746. PubMed ID: 31972133
[TBL] [Abstract][Full Text] [Related]
19. Neutralizing Antibodies Against Adeno-Associated Virus (AAV): Measurement and Influence on Retinal Gene Delivery.
Desrosiers M; Dalkara D
Methods Mol Biol; 2018; 1715():225-238. PubMed ID: 29188517
[TBL] [Abstract][Full Text] [Related]
20. Prevalence and pharmacological modulation of humoral immunity to AAV vectors in gene transfer to synovial tissue.
Mingozzi F; Chen Y; Edmonson SC; Zhou S; Thurlings RM; Tak PP; High KA; Vervoordeldonk MJ
Gene Ther; 2013 Apr; 20(4):417-24. PubMed ID: 22786533
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
